PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
0.92%
Revenue growth near Medical - Pharmaceuticals median of 0.84%. Charlie Munger would verify if industry-standard growth is attractive.
0.32%
Cost increase while Medical - Pharmaceuticals shows cost reduction. Peter Lynch would examine competitive disadvantages.
3.15%
Gross profit growth 50-75% of Medical - Pharmaceuticals median of 4.96%. Guy Spier would scrutinize competitive position.
2.21%
Margin expansion exceeding 1.5x Medical - Pharmaceuticals median of 0.31%. Joel Greenblatt would investigate competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Other expenses reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate advantages.
-2.10%
Operating expenses reduction while Medical - Pharmaceuticals median is 0.85%. Seth Klarman would investigate advantages.
-0.12%
Total costs reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
6.37%
D&A change of 6.37% versus flat Medical - Pharmaceuticals D&A. Walter Schloss would verify adequacy.
22.95%
EBITDA growth 1.25-1.5x Medical - Pharmaceuticals median of 16.44%. Mohnish Pabrai would examine sustainability.
21.83%
EBITDA margin growth exceeding 1.5x Medical - Pharmaceuticals median of 8.24%. Joel Greenblatt would investigate advantages.
28.75%
Operating income growth exceeding 1.5x Medical - Pharmaceuticals median of 10.25%. Joel Greenblatt would investigate advantages.
27.58%
Operating margin growth exceeding 1.5x Medical - Pharmaceuticals median of 3.55%. Joel Greenblatt would investigate advantages.
-25.12%
Other expenses reduction while Medical - Pharmaceuticals median is 13.85%. Seth Klarman would investigate advantages.
25.23%
Pre-tax income growth exceeding 1.5x Medical - Pharmaceuticals median of 13.99%. Joel Greenblatt would investigate advantages.
24.09%
Pre-tax margin growth exceeding 1.5x Medical - Pharmaceuticals median of 8.05%. Joel Greenblatt would investigate advantages.
23.80%
Tax expense change of 23.80% versus flat Medical - Pharmaceuticals. Walter Schloss would verify strategy.
25.93%
Net income growth exceeding 1.5x Medical - Pharmaceuticals median of 13.56%. Joel Greenblatt would investigate advantages.
24.79%
Net margin growth exceeding 1.5x Medical - Pharmaceuticals median of 6.61%. Joel Greenblatt would investigate advantages.
25.93%
EPS growth 1.25-1.5x Medical - Pharmaceuticals median of 17.65%. Mohnish Pabrai would examine sustainability.
25.93%
Diluted EPS growth 1.25-1.5x Medical - Pharmaceuticals median of 17.65%. Mohnish Pabrai would examine sustainability.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.